Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials

Background: Novel combination therapies have been shown to improve the outcomes of treatment-naive patients with locally advanced or metastatic renal cell carcinoma (aRCC). However, the optimal systemic therapy for aRCC of favorable risk has yet to be clarified. We aimed to evaluate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Manneh, Ray, Lema, Mauricio, Carril-Ajuria, Lucía, Ibatá, Linda, Martínez, Susan, Castellano, Daniel, de Velasco, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945232/
https://www.ncbi.nlm.nih.gov/pubmed/35327380
http://dx.doi.org/10.3390/biomedicines10030577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945232/
https://www.ncbi.nlm.nih.gov/pubmed/35327380
http://dx.doi.org/10.3390/biomedicines10030577

Ejemplares similares